The Wistar Institute   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Philadelphia PA United States (1892)

Organization Overview

First Clinical Trial
2007
NCT00100646
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

HIV-1 Immunopathogenesis Laboratory. The Wistar Institute | Luis Montaner | The Wistar Institute | Troy Messick

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Carcinoma (Phase 2)

Communicable Diseases (Phase 2)

HIV Infections (Phase 2)

Infections (Phase 2)

Melanoma (Phase 1)

Nasopharyngeal Carcinoma (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 23